A novel hybrid class of telmisartan–rosiglitazone molecules was synthesized in an attempt to discover a dual peroxisome proliferator-activated receptor gamma (PPARc) agonist/angiotensin II antagonist for treatment for metabolic syndrome. Almost all the synthesized molecules showed moderate PPARc activity. However, none of the hybrid analogs showed binding affinity toward the AT1 receptor.